The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
Open accessAbstract
The mechanisms of malignant cell transformation caused by the oncogenic, chimeric nucleophosmin (NPM)/anaplastic lymphoma kinase (ALK) remain only partially understood, with most of the previous studies focusing mainly on the impact of NPM/ALK on cell survival and proliferation. Here we report that the NPM/ALK-carrying T cell lymphoma (ALK+TCL) cells strongly express the immunosuppressive cell-surface protein CD274 (PD-L1, B7-H1), as determined on the mRNA and protein level. The CD274 expression is strictly dependent on the expression and enzymatic activity of NPM/ALK, as demonstrated by inhibition of the NPM/ALK function in ALK+TCL cells by the small molecule ALK inhibitor CEP-14083 and by documenting CD274 expression in IL-3-depleted BaF3 cells transfected with the wild-type NPM/ALK, but not the kinase-inactive NPM/ALK K210R mutant or empty vector alone. NPM/ALK induces CD274 expression by activating its key signal transmitter, transcription factor STAT3. STAT3 binds to the CD274 gene promoter in vitro and in vivo , as shown in the gel electromobility shift and chromatin immunoprecipitation assays, and is required for the PD-L1 gene expression, as demonstrated by siRNA-mediated STAT3 depletion. These findings identify an additional cell-transforming property of NPM/ALK and describe a direct link between an oncoprotein and an immunosuppressive cell-surface protein. These results also provide an additional rationale to therapeutically target NPM/ALK and STAT3 in ALK+TCL. Finally, they suggest that future immunotherapeutic protocols for this type of lymphoma may need to include the inhibition of NPM/ALK and STAT3 to achieve optimal clinical efficacy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
Morris, S. W., Kirstein, M. N., Valentine, M. B., Dittmer, K. G., Shapiro, D. N., Saltman, D. L., & Look, A. T. (1994) · Science · doi:10.1126/science.8122112 · Cited by 2,409
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“Given that STAT3 can be activated by a variety of quite diverse tyrosine kinases (23), that it is persistently activated in a large spectrum of malignancies and, finally, that the STAT3 activation plays a key role in oncogenesis (24–26), it is likely that STAT3 is involved in inducing immune evasion of a substantial n…”
BackgroundLoss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma
Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2007) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,344
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310 · cited 1×
“response against microorganisms, to protect the involved tissues from excessive damage incurred during such a response and to prevent its potential autoimmune complications (11, 12).”
BackgroundRegulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
The anaplastic lymphoma kinase in the pathogenesis of cancer
Chiarle, R., Voena, C., Ambrogio, C., Piva, R., & Inghirami, G. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2291 · Cited by 882
Liu, J., Hamrouni, A., Wolowiec, D., Coiteux, V., Kuliczkowski, K., Hetuin, D., Saudemont, A., & Quesnel, B. (2007) · Blood · doi:10.1182/blood-2006-10-051482 · Cited by 580
Morris, S. W., Naeve, C., Mathew, P., James, P. L., Kirstein, M. N., Cui, X., & Witte, D. P. (1997) · Oncogene · doi:10.1038/sj.onc.1201062 · Cited by 524
Lee, S.-J., Jang, B.-C., Lee, S.-W., Yang, Y.-I., Suh, S.-I., Park, Y.-M., Oh, S., Shin, J.-G., Yao, S., Chen, L., et al. (2006) · FEBS Letters · doi:10.1016/j.febslet.2005.12.093 · Cited by 446
Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target
Chiarle, R., Simmons, W. J., Cai, H., Dhall, G., Zamo, A., Raz, R., Karras, J. G., Levy, D. E., & Inghirami, G. (2005) · Nature Medicine · doi:10.1038/nm1249 · Cited by 442
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Galkin, A. V., Melnick, J. S., Kim, S., Hood, T. L., Li, N., Li, L., Xia, G., Steensma, R., Chopiuk, G., Jiang, J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609412103 · Cited by 379
A Critical Role for Stat3 Signaling in Immune Tolerance
Cheng, F., Wang, H.-W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00232-2 · Cited by 377
Self-citationBischof, D., Pulford, K., Mason, D. Y., & Morris, S. W. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.4.2312 · Cited by 363
Chan, K. S., Sano, S., Kiguchi, K., Anders, J., Komazawa, N., Takeda, J., & DiGiovanni, J. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421032 · Cited by 356
Fujimoto, J., Shiota, M., Iwahara, T., Seki, N., Satoh, H., Mori, S., & Yamamoto, T. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4181 · Cited by 289
B7-H1 pathway and its role in the evasion of tumor immunity
Dong, H., & Chen, L. (2003) · Journal of Molecular Medicine · doi:10.1007/s00109-003-0430-2 · Cited by 276
Zhang, Q., Raghunath, P. N., Xue, L., Majewski, M., Carpentieri, D. F., Odum, N., Morris, S., Skorski, T., & Wasik, M. A. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.1.466 · Cited by 262
Self-citationNPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors
Chiarle, R., Gong, J. Z., Guasparri, I., Pesci, A., Cai, J., Liu, J., Simmons, W. J., Dhall, G., Howes, J., Piva, R., et al. (2003) · Blood · doi:10.1182/blood-2002-05-1343 · Cited by 252
Shiota, M., Fujimoto, J., Semba, T., Satoh, H., Yamamoto, T. S., & Mori, S. (1994) · PubMed · Cited by 246
Nielsen, M., Kaltoft, K., Nordahl, M., Röpke, C., Geisler, C., Mustelin, T., Dobson, P., Svejgaard, A., & Ødum, N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6764 · Cited by 220
Ling, X., & Arlinghaus, R. B. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2425 · Cited by 201
Kasprzycka, M., Marzec, M., Liu, X., Zhang, Q., & Wasik, M. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603507103 · Cited by 154
Self-citationDevelopment of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy
Li, R., & Morris, S. W. (2007) · Medicinal Research Reviews · doi:10.1002/med.20109 · Cited by 148
Zhang, Q., Wang, H. Y., Liu, X., & Wasik, M. A. (2007) · Nature Medicine · doi:10.1038/nm1659 · Cited by 141
Self-citationThe anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., d’Escamard, V., Forni, G., & Inghirami, G. (2008) · Nature Medicine · doi:10.1038/nm1769 · Cited by 129
Marzec, M., Kasprzycka, M., Liu, X., El-Salem, M., Halasa, K., Raghunath, P. N., Bucki, R., Wlodarski, P. K., & Wasik, M. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210346 · Cited by 116
Self-citationImmune response to the ALK oncogenic tyrosine kinase in patients with anaplastic large-cell lymphoma
Pulford, K., Falini, B., Banham, A. H., et al. (2000) · Blood · doi:10.1182/blood.v96.4.1605 · Cited by 115
Wan, W., Albom, M. S., Lü, L., Quail, M. R., Becknell, N. C., Weinberg, L. R., Reddy, D. R., Holskin, B. P., Angeles, T. S., Underiner, T. L., et al. (2005) · Blood · doi:10.1182/blood-2005-08-3254 · Cited by 111
Self-citationPassoni, L., Scardino, A., Bertazzoli, C., Gallo, B. M., Coluccia, A. M. L., Lemonnier, F. A., Kosmatopoulos, K., & Gambacorti-Passerini, C. B. (2002) · Blood · doi:10.1182/blood.v99.6.2100 · Cited by 101
Marzec, M., Kasprzycka, M., Liu, X., Raghunath, P. N., Wlodarski, P. K., & Wasik, M. A. (2006) · Oncogene · doi:10.1038/sj.onc.1209843 · Cited by 96
Self-citationNielsin, M. (1997) · Proceedings of the National Academy of Sciences · Cited by 93
Marzec, M., Halasa, K., Kasprzycka, M., Wysocka, M., Liu, X., Tobias, J. W., Baldwin, D. A., Zhang, Q., Ødum, N., Rook, A. H., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-2403 · Cited by 81
Self-citationWebster, W. S., Thompson, R. H., Harris, K. J., Frigola, X., Kuntz, S. M., Inman, B. A., & Dong, H. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.2860 · Cited by 81
Marzec, M., Kasprzycka, M., Ptasznik, A., Wlodarski, P. K., Zhang, Q., Ødum, N., & Wasik, M. A. (2005) · Laboratory Investigation · doi:10.1038/labinvest.3700348 · Cited by 73
Self-citationγc-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes
Kasprzycka, M., Zhang, Q., Witkiewicz, A. K., Marzec, M., Potoczek, M., Liu, X., Wang, H. Y., Milone, M. C., Basu, S., Mauger, J., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.4.2506 · Cited by 59
Self-citation
Cited by
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Metadata
- Authors
- Marzec, M., Zhang, Q., Goradia, A., Raghunath, P. N., Liu, X., Paessler, M., Wang, H. Y., Wysocka, M., Cheng, M., Ruggeri, B. A., & Wasik, M. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-12-30
- Volume
- 105
- Issue
- 52
- Pages
- 20852-20857
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2051083170
- Cited by
- 728
- References
- 36
- FWCI
- 4.31
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.